A Philadelphia jury found that the manufacturers of the antipsychotic drug Risperdal failed to warn patients of the risk of male breast growth associated with the drug. The case marks the second time in a month that Janssen Pharmaceuticals and parent company Johnson & Johnson have been found guilty of failing to warn about Risperdal breast growth risks.
In February, an Alabama man was awarded $2.5 million after a jury found that Risperdal caused him to develop gynecomastia, a condition which results in growing breasts. More than 1,300 additional Risperdal lawsuits are filed against Janssen and J&J alleging similar side effects from Risperdal.
The manufacturers also paid more than $2 billion in 2013 after the U.S. government charged them with illegally marketing the drug for unapproved uses. Risperdal has been approved to treat schizophrenia, but is often used in children to treat symptoms of other conditions, including ADHD and bipolar disorder.